Supernus Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US8684591089

SecuritySUPN / Supernus Pharmaceuticals, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership2,712,341 shares
Ownership 4.70%
Dimensional Fund Advisors Lp ownership in SUPN / Supernus Pharmaceuticals, Inc.

2026-01-21 - Dimensional Fund Advisors Lp has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,712,341 shares of Supernus Pharmaceuticals, Inc. (US:SUPN). This represents 4.7 percent ownership of the company. In their previous filing dated 2024-10-31 , Dimensional Fund Advisors Lp had reported owning 2,882,505 shares, indicating a decrease of -5.90 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-01-21 2026-01-21 13G/A 2,882,505 2,712,341 -5.90 4.70 -9.62
2024-10-31 2024-10-31 13G 2,882,505 5.20

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,307,030 -405,311 -14.94 119,239 -11.55 0.0053
2026-02-12 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,712,341 -289,600 -9.65 134,804 -6.03 0.0283
2025-11-12 2025-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 3,001,941 -19,266 -0.64 143,462 50.65 0.0308
2025-08-12 2025-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 3,021,207 117,480 4.05 95,227 0.14 0.0220
2025-05-13 2025-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,903,727 25,182 0.87 95,094 -8.64 0.0236
2025-02-13 2024-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,878,545 -3,960 -0.14 104,092 15.82 0.0250
2024-11-07 2024-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,882,505 15,618 0.54 89,875 17.19 0.0218
2024-08-09 2024-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,866,887 309,966 12.12 76,690 -12.07 0.0200
2024-05-10 2024-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,556,921 100,552 4.09 87,217 22.69 0.0236
2024-02-07 2023-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,456,369 141,586 6.12 71,089 11.39 0.0208
2023-11-09 2023-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,314,783 -116,133 -4.78 63,820 -12.66 0.0209
2023-08-09 2023-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,430,916 39,650 1.66 73,073 -15.65 0.0233
2023-05-12 2023-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,391,266 7,921 0.33 86,636 101,823.53 0.0292
2023-02-09 2022-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,383,345 112,865 4.97 85 -99.89 0.0251
2022-11-10 2022-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,270,480 31,355 1.40 76,854 18.69 0.0295
2022-08-12 2022-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,239,125 17,805 0.80 64,753 -9.81 0.0232
2022-05-13 2022-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,221,320 -19,301 -0.86 71,793 9.88 0.0221
2022-02-09 2021-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,240,621 -34,430 -1.51 65,339 7.69 0.0198
2021-11-12 2021-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,275,051 -1,134 -0.05 60,676 -13.43 0.0195
2021-08-12 2021-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,276,185 144,093 6.76 70,086 25.56 0.0222
2021-05-14 2021-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,132,092 197,229 10.19 55,818 14.66 0.0185
2021-03-08 2020-12-31 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 1,934,863 -29,972 -1.53 48,681 18.89 0.0176
2021-02-11 2020-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,934,863 -29,972 48,681 17,580.9897
2020-11-12 2020-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,964,835 4,824 0.25 40,947 -12.03 0.0174
2020-08-13 2020-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,960,011 143,121 7.88 46,548 42.42 0.0205
2020-05-14 2020-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,816,890 154,883 9.32 32,683 -17.09 0.0170
2020-02-14 2019-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,662,007 59,297 3.70 39,422 -10.49 0.0144
2019-11-12 2019-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,602,710 162,379 11.27 44,043 -7.59 0.0171
2019-08-13 2019-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,440,331 61,765 4.48 47,659 -1.34 0.0185
2019-08-12 2019-03-31 13F/A-2 SUPERNUS PHARMACEUTICALS COM 868459108 1,378,566 64,805 4.93 48,304 10.68 0.0192
2019-05-10 2019-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,378,566 64,805 48,304
2019-02-26 2018-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 1,313,761 -21,130 -1.58 43,642 -35.07 0.0198
2019-02-13 2018-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,313,761 -21,130 43,642
2018-11-13 2018-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,334,891 -15,093 -1.12 67,211 -16.81 0.0256
2018-08-10 2018-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,349,984 -54,010 -3.85 80,795 25.65 0.0322
2018-05-11 2018-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,403,994 4,844 0.35 64,303 15.33 0.0268
2018-02-12 2017-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,399,150 131,726 10.39 55,758 9.99 0.0231
2017-11-13 2017-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,267,424 -658 -0.05 50,696 -7.24 0.0222
2017-08-11 2017-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,268,082 122,042 10.65 54,654 52.36 0.0252
2017-05-12 2017-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,146,040 39,033 3.53 35,871 28.33 0.0171
2017-02-09 2016-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,107,007 51,511 4.88 27,952 7.09 0.0140
2016-11-10 2016-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,055,496 13,480 1.29 26,102 22.97 0.0141
2016-08-09 2016-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,042,016 -5,797 -0.55 21,226 32.84 0.0122
2016-05-13 2016-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,047,813 -39,242 -3.61 15,979 9.37 0.0096
2016-02-10 2015-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,087,055 117,574 12.13 14,610 7.41 0.0091
2015-11-13 2015-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 969,481 465,524 92.37 13,602 58.96 0.0089
2015-08-14 2015-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 503,957 503,957 8,557 0.0052
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.